OneSource Specialty Pharma Limited

As of June 30, 2026, OneSource Specialty Pharma Limited carries a market capitalization of 188.90B, placing it among publicly traded companies globally. Its enterprise value stands at 188.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

OneSource Specialty Pharma Limited's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, OneSource Specialty Pharma Limited has 114.64M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, OneSource Specialty Pharma Limited trades at an EV/EBITDA multiple of 57.64 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 12.24 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 422.68 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 188.90B versus a market cap of 188.90B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 7.60M in revenue per employee across its workforce of 2,031.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, OneSource Specialty Pharma Limited recorded an income tax benefit of -186.48M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -672.68M and -486.20M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, OneSource Specialty Pharma Limited's stock has declined approximately 25.44% over the past 52 weeks. The 50-day moving average sits at 1,527.58, while the 200-day moving average is 1,561.08.

Over the twelve months ended June 30, 2026, OneSource Specialty Pharma Limited generated 15.43B in revenue and converted that into -486.20M in net income, yielding earnings per share of -4.23. EBITDA reached 3.28B, while operating income came in at 560.49M.

Over the twelve months ended June 30, 2026, OneSource Specialty Pharma Limited posted a gross margin of 67.83, reflecting its pricing power and cost economics. The operating margin of 3.63 and net profit margin of -3.15 provide insight into operational efficiency.